119 related articles for article (PubMed ID: 37665720)
1. Size-Tunable Nanoregulator-Based Radiofrequency Ablation Suppresses MDSCs and Their Compensatory Immune Evasion in Hepatocellular Carcinoma.
Tang Y; Shu Z; Zhu M; Li S; Ling Y; Fu Y; Hu Z; Wang J; Yang Z; Liao J; Xu L; Yu M; Peng Z
Adv Healthc Mater; 2023 Dec; 12(30):e2302013. PubMed ID: 37665720
[TBL] [Abstract][Full Text] [Related]
2. Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation.
Zeng X; Liao G; Li S; Liu H; Zhao X; Li S; Lei K; Zhu S; Chen Z; Zhao Y; Ren X; Su T; Cheng AS; Peng S; Lin S; Wang J; Chen S; Kuang M
Hepatology; 2023 Apr; 77(4):1122-1138. PubMed ID: 35598182
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma.
Sun T; Sun B; Cao Y; Liu J; Chen J; Liang B; Zheng C; Kan X
Biomed Pharmacother; 2023 Oct; 166():115351. PubMed ID: 37625323
[TBL] [Abstract][Full Text] [Related]
4. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy.
Zhao Z; Wu J; Liu X; Liang M; Zhou X; Ouyang S; Yao J; Wang J; Luo B
Cancer Lett; 2018 May; 421():73-81. PubMed ID: 29458142
[TBL] [Abstract][Full Text] [Related]
5. Incomplete radiofrequency ablation induced chemoresistance by up-regulating heat shock protein 70 in hepatocellular carcinoma.
Wang F; Xu C; Li G; Lv P; Gu J
Exp Cell Res; 2021 Dec; 409(2):112910. PubMed ID: 34801560
[TBL] [Abstract][Full Text] [Related]
6. Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation.
Shi ZR; Duan YX; Cui F; Wu ZJ; Li MP; Song PP; Peng QL; Ye WT; Yin KL; Kang MQ; Yu YX; Yang J; Tang W; Liao R
J Exp Clin Cancer Res; 2023 May; 42(1):133. PubMed ID: 37231509
[TBL] [Abstract][Full Text] [Related]
7. The HSP90 inhibitor, XL888, enhanced cell apoptosis via downregulating STAT3 after insufficient radiofrequency ablation in hepatocellular carcinoma.
Sun C; Bai M; Ke W; Wang X; Zhao X; Lu Z
Life Sci; 2021 Oct; 282():119762. PubMed ID: 34186047
[TBL] [Abstract][Full Text] [Related]
8. Insufficient radiofrequency ablation-induced autophagy contributes to the rapid progression of residual hepatocellular carcinoma through the HIF-1α/BNIP3 signaling pathway.
Xu WL; Wang SH; Sun WB; Gao J; Ding XM; Kong J; Xu L; Ke S
BMB Rep; 2019 Apr; 52(4):277-282. PubMed ID: 30940322
[TBL] [Abstract][Full Text] [Related]
9. A well-matched marriage of immunotherapy and radiofrequency ablation to reduce the relapse and progression of hepatocellular carcinoma.
Liao R; Song P; Duan Y; Ye W; Yin K; Kang M; Yu Y; Yang J; Tang W
Biosci Trends; 2022 Nov; 16(5):377-380. PubMed ID: 36089338
[TBL] [Abstract][Full Text] [Related]
10. Augmented EPR effect post IRFA to enhance the therapeutic efficacy of arsenic loaded ZIF-8 nanoparticles on residual HCC progression.
Chen X; Huang Y; Chen H; Chen Z; Chen J; Wang H; Li D; Su Z
J Nanobiotechnology; 2022 Jan; 20(1):34. PubMed ID: 35033089
[TBL] [Abstract][Full Text] [Related]
11. Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N6-Methyladenosine mRNA Methylation-Dependent Mechanism.
Su T; Huang M; Liao J; Lin S; Yu P; Yang J; Cai Y; Zhu S; Xu L; Peng Z; Peng S; Chen S; Kuang M
Hepatology; 2021 Sep; 74(3):1339-1356. PubMed ID: 33638162
[TBL] [Abstract][Full Text] [Related]
12. Targeting N
Zhu S; Wu Y; Zhang X; Peng S; Xiao H; Chen S; Xu L; Su T; Kuang M
Mol Ther; 2023 Jun; 31(6):1596-1614. PubMed ID: 35965412
[TBL] [Abstract][Full Text] [Related]
13. STING agonist-based hydrogel enhances immune activation in synergy with radiofrequency ablation for hepatocellular carcinoma treatment.
Ao F; Li X; Tan Y; Jiang Z; Yang F; Guo J; Zhu Q; Chen Z; Zhou B; Zhang K; Li D
J Control Release; 2024 May; 369():296-308. PubMed ID: 38301925
[TBL] [Abstract][Full Text] [Related]
14. Identification of circRNAs involved in the development of hepatocellular carcinoma after insufficient radiofrequency ablation.
Chen JW; Lai LS; Luo JY; Zhou CR; Li MG; Huang MS; Wu P
Neoplasma; 2022 May; 69(3):527-537. PubMed ID: 35144476
[TBL] [Abstract][Full Text] [Related]
15. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
16. Targeting autophagy enhances heat stress-induced apoptosis via the ATP-AMPK-mTOR axis for hepatocellular carcinoma.
Jiang J; Chen S; Li K; Zhang C; Tan Y; Deng Q; Chai Y; Wang X; Chen G; Feng K; Zhang L; Xie CM; Ma K
Int J Hyperthermia; 2019; 36(1):499-510. PubMed ID: 31007109
[TBL] [Abstract][Full Text] [Related]
17. Insufficient radiofrequency ablation promotes hepatocellular carcinoma cell progression via autophagy and the CD133 feedback loop.
Wang X; Deng Q; Feng K; Chen S; Jiang J; Xia F; Ma K; Bie P
Oncol Rep; 2018 Jul; 40(1):241-251. PubMed ID: 29749472
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.
Mizukoshi E; Yamashita T; Arai K; Sunagozaka H; Ueda T; Arihara F; Kagaya T; Yamashita T; Fushimi K; Kaneko S
Hepatology; 2013 Apr; 57(4):1448-57. PubMed ID: 23174905
[TBL] [Abstract][Full Text] [Related]
19. Letter to the Editor: Is eliminating METTL1-mediated accumulation of PMN-MDSCs sufficient to prevent hepatocellular carcinoma recurrence after radiofrequency ablation?
Yang F; Jiang S; Zheng Y
Hepatology; 2023 Apr; 77(4):E62-E63. PubMed ID: 35753066
[No Abstract] [Full Text] [Related]
20. Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response.
Qi X; Yang M; Ma L; Sauer M; Avella D; Kaifi JT; Bryan J; Cheng K; Staveley-O'Carroll KF; Kimchi ET; Li G
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33115942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
